ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors

Zhang, Jian; Dong, Yue; Gao, Shenghua; Zhang, Xujie; Liao, Hui; Shi, Xiaoyu; Zhang, Zhijiao; Zhao, Tong; Liang, Ruipeng; Qi, Danhui; Wu, Ting*; Pang, Jianxin*; Liu, Xinyong*; Zhan, Peng*南方医科大学; 山东大学
European Journal of Medicinal Chemistry2022-12-15DOI: 10.1016/j.ejmech.2022.114816
3被引8阅读
引用收藏
分享

摘要

Urate Transporter 1 (URAT1) plays a crucial role in uric acid transport, making it an attractive target for the treatment of gout and hyperuricemia. As a representative URAT1 inhibitor, Lesinurad treat gout by promoting the uric acid excretion. However, its lower in vitro and in vivo activity should be highly attracted attention. Herein, the bioisosterism, molecular hybridization and scaffold hopping strategies were exploited to modify all the structural components of Lesinurad and finally thirty novel compounds bearing thienopyrimidinone or pyridine core were obtained. Most of the compounds displayed certain URAT1 inhibitory activity in vitro. Among them, thienopyrimidinones 6 (IC50 = 7.68 mu M), 10 (IC50 = 7.56 mu M), 14 (IC50 = 7.31 mu M) and 15 (IC50 = 7.90 mu M) showed slightly better potency than positive control Lesinurad (IC50 = 9.38 mu M). Notably, 10 also displayed inhibitory activity (IC50 = 55.96 mu M) against GLUT9. Additionally, in vivo serum uric acid (SUA)-lowering experiments were performed on some representative compounds and it was revealed that all the selected compounds could decrease the SUA level in mice, of which the decrease rate of SUA was 73.29% for the most promising compound 10, significantly greater than that of Lesinurad (26.89%). Meanwhile, the preliminary SARs based on the URAT1 inhibitory activity were discussed in detail, which pointed out the direction for further structural optimization. Overall, the thienopyrimidinone and pyridine are prospective skeletons for the developing novel URAT1 inhibitors with considerable potential for optimization.

学科与关键词

关键词
URAT1 inhibitorsGoutHyperuricemiaLesinuradThienopyrimidinonePyridine
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
European Journal of Medicinal Chemistry
发表日期
2022-12-15
卷期
第 244 卷
页码
114816
DOI
10.1016/j.ejmech.2022.114816
语言
MULTI-LANGUAGE
期刊等级
1区
成果收录
SCIE
资助标注
Shandong Provincial Key Research and Development Project [2019JZZY021011]; Science Foundation for Outstanding Young Scholars of Shandong Province [ZR2020JQ31]; Foreign Cultural and Educational Experts Project [GXL20200015001]; Qilu Young Scholars Program of Shandong University; Guangzhou Science and Technology Program Project [201903010087]; Natural Science Foundation of China [81773794, 81974507]; Taishan Scholar Program at Shandong Province

作者

  • Z

    Zhang, Jian (第一作者)

    shandong univ

  • D

    Dong, Yue

    shandong univ

查看全部 14 位作者收起作者
  • G

    Gao, Shenghua

    shandong univ

  • Z

    Zhang, Xujie

    shandong univ

  • L

    Liao, Hui

    southern med univ

  • S

    Shi, Xiaoyu

    shandong univ

  • Z

    Zhang, Zhijiao

    shandong univ

  • Z

    Zhao, Tong

    shandong univ

  • L

    Liang, Ruipeng

    shandong univ

  • Q

    Qi, Danhui

    shandong univ

  • W

    Wu, Ting (通讯)

    southern med univ

  • P

    Pang, Jianxin (通讯)

    southern med univ

  • L

    Liu, Xinyong (通讯)

    shandong univ

  • Z

    Zhan, Peng (通讯)

    shandong univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417